Efficacy of Lenvervimab, a Recombinant Human Immunoglobulin, in Treatment of Chronic Hepatitis B Virus Infection

Hye Won Lee; Jun Yong Park; Taegon Hong; Min Soo Park; Sang Hoon Ahn

doi:10.1016/j.cgh.2019.09.038

Efficacy of Lenvervimab, a Recombinant Human Immunoglobulin, in Treatment of Chronic Hepatitis B Virus Infection

Hye Won Lee, Jun Yong Park, Taegon Hong, Min Soo Park, Sang Hoon Ahn

Department of Internal Medicine

Research output: Contribution to journal › Short survey › peer-review

3 Citations (Scopus)

Abstract

The mechanism of action of hepatitis B immunoglobulin (HBIG) for chronic hepatitis B (CHB) treatment is not fully understood. A clinical trial in Japan suggested that HBIG therapy might benefit patients with CHB.¹ Lenvervimab, a recombinant monoclonal HBIG developed by GC Pharma (Yongin, South Korea), has been screened from an anti–HBs-enriched phage-display library cloned from hepatitis B vaccine-boosted human blood cells and was produced in Chinese hamster ovary cells.^2–4

Original language	English
Pages (from-to)	3043-3045.e1
Journal	Clinical Gastroenterology and Hepatology
Volume	18
Issue number	13
DOIs	https://doi.org/10.1016/j.cgh.2019.09.038
Publication status	Published - 2020 Dec

Bibliographical note

Funding Information:
Funding Supported by GC Pharma Co Ltd.

All Science Journal Classification (ASJC) codes

Hepatology
Gastroenterology

Access to Document

10.1016/j.cgh.2019.09.038

Fingerprint Dive into the research topics of 'Efficacy of Lenvervimab, a Recombinant Human Immunoglobulin, in Treatment of Chronic Hepatitis B Virus Infection'. Together they form a unique fingerprint.

Cite this

@article{314fdbcdec634cfabef43ef970ea270d,

title = "Efficacy of Lenvervimab, a Recombinant Human Immunoglobulin, in Treatment of Chronic Hepatitis B Virus Infection",

abstract = "The mechanism of action of hepatitis B immunoglobulin (HBIG) for chronic hepatitis B (CHB) treatment is not fully understood. A clinical trial in Japan suggested that HBIG therapy might benefit patients with CHB.1 Lenvervimab, a recombinant monoclonal HBIG developed by GC Pharma (Yongin, South Korea), has been screened from an anti–HBs-enriched phage-display library cloned from hepatitis B vaccine-boosted human blood cells and was produced in Chinese hamster ovary cells.2–4",

author = "Lee, {Hye Won} and Park, {Jun Yong} and Taegon Hong and Park, {Min Soo} and Ahn, {Sang Hoon}",

note = "Funding Information: Funding Supported by GC Pharma Co Ltd. ",

year = "2020",

month = dec,

doi = "10.1016/j.cgh.2019.09.038",

language = "English",

volume = "18",

pages = "3043--3045.e1",

journal = "Clinical Gastroenterology and Hepatology",

issn = "1542-3565",

publisher = "W.B. Saunders Ltd",

number = "13",

}

TY - JOUR

T1 - Efficacy of Lenvervimab, a Recombinant Human Immunoglobulin, in Treatment of Chronic Hepatitis B Virus Infection

AU - Lee, Hye Won

AU - Park, Jun Yong

AU - Hong, Taegon

AU - Park, Min Soo

AU - Ahn, Sang Hoon

N1 - Funding Information: Funding Supported by GC Pharma Co Ltd.

PY - 2020/12

Y1 - 2020/12

N2 - The mechanism of action of hepatitis B immunoglobulin (HBIG) for chronic hepatitis B (CHB) treatment is not fully understood. A clinical trial in Japan suggested that HBIG therapy might benefit patients with CHB.1 Lenvervimab, a recombinant monoclonal HBIG developed by GC Pharma (Yongin, South Korea), has been screened from an anti–HBs-enriched phage-display library cloned from hepatitis B vaccine-boosted human blood cells and was produced in Chinese hamster ovary cells.2–4

AB - The mechanism of action of hepatitis B immunoglobulin (HBIG) for chronic hepatitis B (CHB) treatment is not fully understood. A clinical trial in Japan suggested that HBIG therapy might benefit patients with CHB.1 Lenvervimab, a recombinant monoclonal HBIG developed by GC Pharma (Yongin, South Korea), has been screened from an anti–HBs-enriched phage-display library cloned from hepatitis B vaccine-boosted human blood cells and was produced in Chinese hamster ovary cells.2–4

UR - http://www.scopus.com/inward/record.url?scp=85090465896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85090465896&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2019.09.038

DO - 10.1016/j.cgh.2019.09.038

M3 - Short survey

C2 - 31589980

AN - SCOPUS:85090465896

VL - 18

SP - 3043-3045.e1

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 13

ER -